Blueprint Medicines Corp
BPMC89.500USD
+1.019+1.15%
Close 04/30, 16:00（ET）Quotes delayed by 15 min
5.70BMarket Cap
LossP/E TTM
More Details of Blueprint Medicines Corp Company
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Company Info
Company codeBPMC
Company nameBlueprint Medicines Corp
IPO dateApr 30, 2015
Founded at2008
CEOMs. Kathryn D (Kate) Haviland
Number of employees649
Security typeOrdinary Share
Fiscal year-endApr 30
Address45 Sidney Street
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02139
Phone16173747580
Websitehttps://www.blueprintmedicines.com/
Company codeBPMC
IPO dateApr 30, 2015
Founded at2008
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Chairman of the Board
Chairman of the Board
142.51K
+4.75%
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
43.17K
+20.54%
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
42.00K
+20.92%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Dr. Christopher K. Murray, Ph.D.
Dr. Christopher K. Murray, Ph.D.
Executive Vice President, Chief Technical Operations and Quality Officer
Executive Vice President, Chief Technical Operations and Quality Officer
28.60K
+48.63%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
23.94K
-13.94%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.09K
+56.18%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
+19.95%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Chairman of the Board
Chairman of the Board
142.51K
+4.75%
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
43.17K
+20.54%
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
42.00K
+20.92%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024Q3
FY2024Q2
FY2024Q1
By BusinessUSD
Name
Revenue
Proportion
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
113.13M
88.26%
Rest of the world
15.05M
11.74%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
Shareholder
Update time: Sun, Feb 23
Update time: Sun, Feb 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
10.47%
T. Rowe Price Associates, Inc.
8.70%
BlackRock Institutional Trust Company, N.A.
7.74%
Wellington Management Company, LLP
6.63%
State Street Global Advisors (US)
3.87%
Other
62.58%
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
10.47%
T. Rowe Price Associates, Inc.
8.70%
BlackRock Institutional Trust Company, N.A.
7.74%
Wellington Management Company, LLP
6.63%
State Street Global Advisors (US)
3.87%
Other
62.58%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
49.33%
Investment Advisor
40.93%
Hedge Fund
10.05%
Research Firm
2.72%
Sovereign Wealth Fund
1.10%
Individual Investor
1.08%
Venture Capital
1.04%
Pension Fund
0.55%
Bank and Trust
0.45%
Institutional Shareholding
Update time: Mon, Feb 24
Update time: Mon, Feb 24
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
658
69.72M
107.98%
-1.29M
2024Q4
657
69.17M
108.25%
-2.83M
2024Q3
644
67.12M
105.97%
-7.85M
2024Q2
622
68.23M
108.95%
-6.94M
2024Q1
615
67.81M
110.73%
-5.62M
2023Q4
612
65.87M
108.35%
-10.02M
2023Q3
602
66.47M
109.56%
-7.64M
2023Q2
614
65.78M
108.78%
-8.60M
2023Q1
625
65.63M
109.42%
-10.28M
2022Q4
635
64.56M
107.90%
-8.82M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
6.76M
10.58%
+90.23K
+1.35%
Dec 31, 2024
T. Rowe Price Associates, Inc.
5.62M
8.79%
+315.30K
+5.94%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.00M
7.82%
+13.26K
+0.27%
Dec 31, 2024
Wellington Management Company, LLP
4.28M
6.7%
+316.75K
+7.99%
Dec 31, 2024
State Street Global Advisors (US)
2.50M
3.91%
-265.50K
-9.60%
Dec 31, 2024
William Blair Investment Management, LLC
1.94M
3.04%
+269.90K
+16.12%
Dec 31, 2024
Fidelity Management & Research Company LLC
1.69M
2.64%
-1.98M
-53.96%
Dec 31, 2024
Geode Capital Management, L.L.C.
1.49M
2.33%
+9.91K
+0.67%
Dec 31, 2024
Macquarie Investment Management
1.26M
1.97%
-4.68K
-0.37%
Dec 31, 2024
Avoro Capital Advisors LLC
1.19M
1.85%
+1.19M
--
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
Invesco Biotechnology & Genome ETF
2.8%
WisdomTree BioRevolution Fund
2.56%
Tema Oncology ETF
2.52%
Range Cancer Immunotherapy ETF
1.97%
SPDR S&P Biotech ETF
1.82%
Virtus LifeSci Biotech Products ETF
1.68%
Direxion Daily S&P Biotech Bull 3X Shares
1.16%
American Century Focused Dynamic Growth ETF
1.02%
iShares Health Innovation Active ETF
0.88%
JPMorgan Fundamental Data Science Small Core ETF
0.88%
View more
Invesco Biotechnology & Genome ETF
Proportion2.8%
WisdomTree BioRevolution Fund
Proportion2.56%
Tema Oncology ETF
Proportion2.52%
Range Cancer Immunotherapy ETF
Proportion1.97%
SPDR S&P Biotech ETF
Proportion1.82%
Virtus LifeSci Biotech Products ETF
Proportion1.68%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.16%
American Century Focused Dynamic Growth ETF
Proportion1.02%
iShares Health Innovation Active ETF
Proportion0.88%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.88%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data